NUCLIDIUM raises CHF 26 M

NUCLIDIUM develops copper-based radiotheranostics for cancer diagnosis and treatment. It has closed a CHF 26 million Series B extension, bringing the round to CHF 105 million, to fund expanded phase 1/2 trials and production.

Announced on
Round
Series B
Amount
CHF 26 M
Location
Basel, canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

  • Kurma Growth Opportunities Fund lead
  • Angelini Ventures lead
  • Aurea lead
  • Wellington Partners lead
  • Neva SGR lead
  • DeepTech & Climate Fonds
  • Bayern Kapital
  • Vives Partners
  • NRW.BANK

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic